[
1. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 2003;64:S24–S31.10.1046/j.1523-1755.64.s87.5.x
]Search in Google Scholar
[
2. Reddan DN, Szczech LA, Tuttle RH Jr., Shaw KL, Jones HR, Schwab JS, et al.. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol. 2003;14(9):2373–2380.10.1097/01.ASN.0000083900.92829.F5
]Search in Google Scholar
[
3. Patel B, Shah M, Dusaj R, Maynard S, Patel N. Percutaneous coronary intervention and inpatient mortality in patients with advanced chronic kidney disease presenting with acute coronary syndrome. Proc (Bayl Univ Med Cent). 2017;30(4):400-403.10.1080/08998280.2017.11930205
]Search in Google Scholar
[
4. Piccolo R, Giustino G, Mehran R, Windecker S. Stable coronary artery disease: revascularization and invasive strategies. Lancet 2015; 386:70210.1016/S0140-6736(15)61220-X
]Search in Google Scholar
[
5. Milojevic M, Head SJ, Mack MJ, Mohr FW, Morice MC, Dawkins KD, et al. The impact of chronic kidney disease on outcomes following percutaneous coronary intervention versus coronary artery bypass grafting in patients with complex coronary artery disease: five-year follow-up of the SYNTAX trial. Eurointervention 2018;14:102–111.10.4244/EIJ-D-17-0062029155387
]Search in Google Scholar
[
6. Giustino G, Mehran R, Serruys PW, Sabik JF 3rd, Milojevic M, Simonton CA, et al. Left main revascularization with PCI or CABG in patients with chronic kidney disease: EXCEL trial. J Am Coll Cardiol. 2018;72:754-765.10.1016/j.jacc.2018.05.05730092952
]Search in Google Scholar
[
7. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. (2015) Revascularization in patients with multivessel coronary artery disease and chronic kidney disease: everolimus-eluting stents versus coronary artery bypass graft surgery. J Am Coll Cardiol 66:1209–1220.10.1016/j.jacc.2015.06.1334494484526361150
]Search in Google Scholar
[
8. Louvard Y, Medina A. Definitions and classifications of bifurcation lesions and treatment. Euro-Intervention. 2015;11 Suppl V:V23-6.10.4244/EIJV11SVA525983165
]Search in Google Scholar
[
9. SYNTAX score. http://www.syntaxscore.com/index.php.Последнапосетана 13.02.2021 г.
]Search in Google Scholar
[
10. Torres IR, Mercader SI, Rumbeu CC, Gil J, Cervelló F, Viana MM, et al. Long-term prognosis of chronic kidney disease in non-ST elevation acute coronary syndrome treated with invasive strategy. Nefrología (English Edition) 2017.37(3):276-284.10.1016/j.nefroe.2017.06.001
]Search in Google Scholar
[
11. Menéndez EG, Vidas MM, Alique M, Carracedo J, Sequera P, Corchete E, et al. Statins and anti-platelet agents are associated with changes in the circulatory markers of endothelial dysfunction in chronic kidney disease. Nefrología (English Edition) 2019;39(3): 287-293.10.1016/j.nefroe.2019.01.002
]Search in Google Scholar
[
12. Kashiyama K, Sonoda S, Muraoka Y., Suzuki Y, Kamezaki F, Tsuda, Y, et al. Coronary plaque progression of non-culprit lesions after culprit percutaneous coronary intervention in patients with moderate to advanced chronic kidney disease: intravascular ultrasound and integrated backscatter intravascular ultrasound study. Int J Cardiovasc Imaging 2015;31:935–945.10.1007/s10554-015-0633-y
]Search in Google Scholar
[
13. Wang C, Cheng G, Duanmu Y, Zhu Y, Xu L. Correlation of coronary plaque characteristics and obstructive stenosis with chronic kidney disease by coronary CT angiography. Cardiovasc Diagn Ther. 2015;5(6):435-443.
]Search in Google Scholar
[
14. Chen W, Melamed ML. Vascular calcification in predialysis CKD: Common and deadly. Clinical J Am Soc Nephrology 2015;10(4):551-553.10.2215/CJN.01940215
]Search in Google Scholar
[
15. Conti CR, Selby JH, Christie LG, Pepine CJ, Curry Jr RC, Nichols WW, et al. Left main coronary artery stenosis: clinical spectrum, patho-physiology, and management. Prog Cardiovasc Dis. 1979;22(2):73–106.10.1016/0033-0620(79)90016-1
]Search in Google Scholar
[
16. Sousa-Uva M, Neumann FJ, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 2019 Jan 1;55(1):4-90.
]Search in Google Scholar
[
17. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr ED, Ganiats GT, Holmes Jr RD, et al. AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139–e228.10.1016/j.jacc.2014.09.017
]Search in Google Scholar
[
18. Holm RN, Makikallio T, Lindsay MM, Spence SM, Erglis A, Menown BI, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomized, non-inferiority NOBLE trial. Lancet 2019;395(10219):191-199.10.1016/S0140-6736(19)32972-1
]Search in Google Scholar
[
19. Han-Yan L, Chih-Hsiang C, Cheng-Chia L, Chien-Chia W, Dong-Yi C, Pao-Hsien C, et al. Risk analysis of dialysis-dependent patients who underwent coronary artery bypass grafting. Medicine 2017; 96(39):e814610.1097/MD.0000000000008146
]Search in Google Scholar
[
20. Wang Z, Gong Y, Fan F, Yang F, Qiu L, Hong T, Huo Y. Coronary artery bypass grafting vs. drug-eluting stent implantation in patients with end-stage renal disease requiring dialysis. Ren Fail. 2020;42(1):107-112.10.1080/0886022X.2019.1710187
]Search in Google Scholar
[
21. Riley RF, Henry TD, Mahmud E, Kirtane JA, Brilakis E, Goyal A, et al. SCAI position statement on optimal percutaneous coronary interventional therapy for complex coronary artery disease. Catheter Cardiovasc Interv. 2020;96:346–362.10.1002/ccd.28994
]Search in Google Scholar
[
22. SUMMARY OF PRODUCT CHARACTERISTICS: PRASUGREL https://www.ema.europa.eu/en/documents/product-information/prasugrel-mylan-epar-product-information_en.pdf. Последна посета на 13.02.2021 г.
]Search in Google Scholar
[
23. Summaria F, Giannico MB, Talarico GP, Patrizi R. Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions. Nephrourol Mon. 2015;7(4):e2809910.5812/numonthly.28099
]Search in Google Scholar
[
24. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRI-TON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723–31.10.1016/S0140-6736(09)60441-4
]Search in Google Scholar
[
25. Small DS, Wrishko RE, Ernest Ii CS, Ni L, Winters KJ, Farid NA, et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther. 2009;34(5):585–94.10.1111/j.1365-2710.2009.01068.x19744014
]Search in Google Scholar
[
26. Park S, KimY, Jo AH, Lee S, Kim M-S, Yang RB, et al. Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent implantation in dialysis patients. Clin Kidney J, 2020;13(5):803–812.10.1093/ckj/sfaa037757776233125004
]Search in Google Scholar
[
27. Amabile N, Rangé G, Souteyrand G, Godin M, Boussaada MM, Meneveau N, et al. Optical Coherence Tomography to Guide Percutaneous Coronary Intervention of the Left Main Coronary Artery: the LEMON study. EuroIntervention 2020; Jaa-868.10.4244/EIJ-D-20-0112133226003
]Search in Google Scholar
[
28. Takagi K., Nagoshi R, Kim BK,, Kim W, Kinoshita Y, Shite J, et al. Efficacy of coronary imaging on bifurcation intervention. Cardiovasc Interv and Ther 2021;36:54–6610.1007/s12928-020-00701-2782922632894433
]Search in Google Scholar
[
29. Cortese B, Burzotta F, Alfonso F, Pellegrini D, Trani C, Aurigemma C, et al. Role of optical coherence tomography for distal left main stem angioplasty. Catheter Cardiovasc Interv.2019;1–7.10.1002/ccd.2854731631525
]Search in Google Scholar
